Provided by Tiger Trade Technology Pte. Ltd.

Heron Therapeutics

0.3182
+0.00922.98%
Pre-market: 0.33000.0118+3.71%05:02 EDT
Volume:3.02M
Turnover:959.46K
Market Cap:60.14M
PE:-1.73
High:0.3330
Open:0.3106
Low:0.3100
Close:0.3090
52wk High:1.58
52wk Low:0.2975
Shares:189.00M
Float Shares:147.00M
Volume Ratio:1.09
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1842
EPS(LYR):-0.1211
ROE:-2408.88%
ROA:-2.80%
PB:10.27
PE(LYR):-2.63

Loading ...

U.S. District Court Issues Decision Regarding Cinvanti® Patents

THOMSON REUTERS
·
Jun 02

Heron Therapeutics - to Appeal Patent Decision to Federal Circuit Court

THOMSON REUTERS
·
Jun 02

Heron Therapeutics - U.S. Court Rules Asserted Claims of Heron's Cinvanti Patents Invalid

THOMSON REUTERS
·
Jun 02

Delaware court invalidates Heron Cinvanti patent claims in Azurity litigation

Reuters
·
Jun 02

Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility

TIPRANKS
·
May 12

Heron Therapeutics Signals Recovery Despite Soft Q1

TIPRANKS
·
May 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)

TIPRANKS
·
May 12

Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright

TIPRANKS
·
May 12

Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M

TIPRANKS
·
May 12

Heron Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Heron Therapeutics' Q1 revenue falls as oncology sales drop

Reuters
·
May 11

Heron Therapeutics Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $34.711M Miss $38.350M Estimate

Benzinga Earnings
·
May 11

BRIEF-Heron Therapeutics Q1 EPS USD -0.04

Reuters
·
May 11

Heron Therapeutics Inc: Reaffirmed 2026 Full-Year Guidance of $173-$183 Mln Net Revenue

THOMSON REUTERS
·
May 11

Heron Therapeutics Q1 Net Product Sales USD 34.711 Million

THOMSON REUTERS
·
May 11

Heron Therapeutics Q1 Operating Expenses USD 28.838 Million

THOMSON REUTERS
·
May 11

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

GlobeNewswire
·
May 11

Heron Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview

Reuters
·
May 08

Heron Therapeutics to report first-quarter results, host conference call and webcast

Reuters
·
Apr 28

Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward

TIPRANKS
·
Apr 17